Impact du traitement initial par upadacitinib ou adalimumab sur l'atteinte des objectifs thérapeutiques à 48 semaines chez les patients atteints de polyarthrite rhumatoïde : analyse post hoc de SELECT-COMPARE
Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keac477
Post hoc analysis findings provide the first data evaluating the importance of treatment order with JAKinib vs TNFi as initial therapy, suggesting that a JAKinib first strategy leads to more rapid improvements in treatment outcomes following csDMARD failure.
With a treat-to-target approach showing improvement in both clinical and functional outcomes, Mysler, et al. evaluate the importance of treatment sequencing in SELECT-COMPARE, assessing potential differences between starting upadacitinib or adalimumab therapy following inadequate MTX response.
Keywords:
